MWMadeleine M. Waldram

Madeleine M. Waldram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Madeleine M. Waldram has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Two‐Center Randomized Controlled Trial to Assess Financial Incentives for Compliance With Living Kidney Donor Follow‐Up in the United States

    by Shivani S. Bisen, Tanveen Ishaque, Alvin G. Thomas, Madeleine M. Waldram, Daniel S. Warren, Jaclyn Bannon, Joseph R. Scalea, Dorry L. Segev, Jacqueline M. Garonzik‐Wang, Allan B. Massie, et al.

    Introduction: The United States Organ Procurement and Transplantation Network mandates collection of 6‐month, 1‐year, and 2‐year post‐donation follow‐up data on living kidney donors (LKDs), but many centers struggle to meet these requirements. This study investigated whether providing a financial incentive (mailed gift card) could increase patient compliance with LKD follow‐up. Methods: A parallel, non‐blinded, 1:1 superiority randomized control trial of LKDs was conducted at two centers from March 2017 to February 2021. The control arm received standard of care (SOC): instructions to complete the mandated LKD follow‐up consisting of a health questionnaire and laboratory measurements at 6 months, 1 year, and 2 years post‐donation. The intervention arm received SOC and was mailed a $25 gift card for each timely completed follow‐up. Compliance rates were compared at each timepoint using Poisson regression. Results: A total of 175 donors consented to participate. The 6‐month, 1‐year, and 2‐year follow‐up compliance rates were 65.2%, 63%, and 65.2% in the control arm, and 71.1%, 60.2%, and 53.0% in the intervention arm, respectively. No statistically significant improvement in compliance was observed with the gift card intervention (IRR = 0.89 1.09 1.34 at 6 months, 0.76 0.96 1.21 at 1 year, and 0.63 0.81 1.05 at 2 years). Similarly, no differences were observed in compliance with clinical follow‐up, laboratory follow‐up, or individual questions or lab values. Conclusion: Mailed gift cards did not improve patient compliance with LKD follow‐up requirements; such interventions may be counterproductive among LKDs. Further research is needed to investigate and address barriers to completing LKD follow‐up. Trial Registration: ClinicalTrials.gov identifier: NCT03090646


  • Effectiveness of a Mobile Health System on Compliance With 2‐Year Living Kidney Donor Follow‐Up in the United States

    by Alvin G. Thomas, Sarah Hussain, Samantha B. Klitenic, Carolyn N. Sidoti, Madeleine M. Waldram, Amy Chang, Jennifer D. Motter, Kelly Terlizzi, Allan B. Massie, Mary Schofield, et al.

    Background: Organ Procurement and Transplantation Network (OPTN) policy requires 2 years of follow‐up for living kidney donors (LKDs); however, many transplant hospitals struggle to meet this requirement. We developed and tested a mobile health (mHealth) system for LKD follow‐up in a pilot randomized‐controlled trial (RCT).Methods: LKDs were randomly assigned to either the intervention (mHealth + standard of care) or control arm (standard of care). We assessed OPTN policy‐defined completeness and timeliness of 6‐month, 1‐year, and 2‐year follow‐ups. Four hundred LKDs were enrolled in the study (June 2018 to February 2021).Results: At 6‐month follow‐up, a higher proportion of the intervention arm participants completed composite visits (97.5% vs. 91.5%, p = 0.01). Both arms had similar compliance rates at 1‐ and 2‐year follow‐up (92.0% vs. 89.5%, p = 0.49, and 66.5% vs. 65.0%, p = 0.83). Intervention arm participants completed 6‐month follow‐up 11 days earlier than their counterparts (p = 0.009).Conclusion: mHealth technologies improved 6‐month follow‐up, but did not impact 1‐ and 2‐year LKD follow‐up in this single‐center RCT. Other strategies, such as providing services beyond data collection, may be necessary to improve donor engagement and support LDK's long‐term follow‐up.


  • Open Access

    Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation

    by Jennifer D. Motter, Kyle R. Jackson, Jane J. Long, Madeleine M. Waldram, Babak J. Orandi, Robert A. Montgomery, Mark D. Stegall, Stanley C. Jordan, Enrico Benedetti, Ty B. Dunn, et al.


  • Open Access

    Quantifying infection risks in incompatible living donor kidney transplant recipients

    by Robin K. Avery, Jennifer D. Motter, Kyle R. Jackson, Robert A. Montgomery, Allan B. Massie, Edward S. Kraus, Kieren A. Marr, Bonnie E. Lonze, Nada Alachkar, Mary J. Holechek, et al.


  • Brief Report: Willingness to Accept HIV-Infected and Increased Infectious Risk Donor Organs Among Transplant Candidates Living With HIV

    by Shanti M. Ba Seaman, Sarah E. Ba Van Pilsum Rasmussen, Anh Q. Ba Nguyen, Samantha E. Ba Halpern, Susan Ba You, Madeleine M. Ba Waldram, Saad K. Ba Anjum, Mary Grace Bowring, Abimereki D. Muzaale, Darin B. Ostrander, et al.

    Background: HIV-infected (HIV+) donor to HIV+ recipient (HIV D+/R+) transplantation might improve access to transplantation for people living with HIV. However, it remains unknown whether transplant candidates living with HIV will accept the currently unknown risks of HIV D+/R+ transplantation. Methods: We surveyed transplant candidates living with HIV from 9 US transplant centers regarding willingness to accept HIV+ donor organs. Results: Among 116 participants, the median age was 55 years, 68% were men, and 78% were African American. Most were willing to accept HIV+ living donor organs (87%), HIV+ deceased donor organs (84%), and increased infectious risk donor organs (70%). Some (30%) were concerned about HIV superinfection; even among these respondents, 71% were willing to accept an HIV D+ organ. Respondents from centers that had already performed a transplant under an HIV D+/R+ transplantation research protocol were more willing to accept HIV+ deceased donor organs (89% vs. 71%, P = 0.04). Respondents who chose not to enroll in an HIV D+/R+ transplantation research protocol were less likely to believe that HIV D+/R+ transplantation was safe (45% vs. 77%, P = 0.02), and that HIV D+ organs would work similar to HIV D− organs (55% vs. 77%, P = 0.04), but more likely to believe they would receive an infection other than HIV from an HIV D+ organ (64% vs. 13%, P < 0.01). Conclusions: Willingness to accept HIV D+ organs among transplant candidates living with HIV does not seem to be a major barrier to HIV D+/R+ transplantation and may increase with growing HIV D+/R+ transplantation experience.


  • Long‐term renal function in living kidney donors with simple renal cysts: A retrospective cohort study

    by Madeleine M. Waldram, Alvin G. Thomas, Yifan Yu, Courtenay M. Holscher, Anh Q. Nguyen, Samantha E. Halpern, Shane Ottman, Abimereki D. Muzaale, Macey L. Henderson, Krista L. Lentine, et al.

    Simple (Bosniak I) renal cysts are considered acceptable in living kidney donor selection in terms of cancer risk. However, they tend to increase in number and size over time and might compromise renal function in donors. To clarify their implications for long‐term renal function, we characterized the prevalence of renal cysts in 454 individuals who donated at our center from 2000 to 2007. We estimated the association between the presence of cysts in the kidney remaining after nephrectomy (ie, retained cysts) and postdonation eGFR trajectory using mixed‐effects linear regression. Donors with retained cysts (N = 86) were older (P < .001) and had slightly lower predonation eGFR (median 94 vs 98 mL/min/1.73 m2,P < .01) than those without cysts. Over a median 7.8 years, donors with retained cysts had lower baseline eGFR (−8.7−5.6−2.3 mL/min/1.73 m2,P < .01) but similar yearly change in eGFR (−0.40.020.4 mL/min/1.73 m2,P = .2) compared to those without retained cysts. Adjusting for predonation characteristics, there was no difference in baseline eGFR (P = .6) or yearly change in eGFR (P > .9). There continued to be no evidence of an association when we considered retained cyst(s) ≥10 mm or multiple retained cysts (allP > .05). These findings reaffirm current practices of accepting candidates with simple renal cysts for donor nephrectomy.


  • Open Access

    Living donor program crisis management plans: Current landscape and talking point recommendations

    by Macey L. Henderson, Rebecca Hays, Sarah E. Van Pilsum Rasmussen, Didier A. Mandelbrot, Krista L. Lentine, Daniel G. Maluf, Madeleine M. Waldram, Matthew Cooper


  • Perspectives on implementing mobile health technology for living kidney donor follow‐up: In‐depth interviews with transplant providers

    by Ann K. Eno, Jessica M. Ruck, Sarah E. Van Pilsum Rasmussen, Madeleine M. Waldram, Alvin G. Thomas, Tanjala S. Purnell, Jacqueline M. Garonzik Wang, Allan B. Massie, Fawaz Al Almmary, Lisa M. Cooper, et al.

    Background: United States transplant centers are required to report follow‐up data for living kidney donors for 2 years post‐donation. However, living kidney donor (LKD) follow‐up is often incomplete. Mobile health (mHealth) technologies could ease data collection burden but have not yet been explored in this context.Methods: We conducted semi‐structured in‐depth interviews with a convenience sample of 21 transplant providers and thought leaders about challenges in LKD follow‐up, and the potential role of mHealth in overcoming these challenges.Results: Participants reported challenges conveying the importance of follow‐up to LKDs, limited data from international/out‐of‐town LKDs, and inadequate staffing. They believed the 2‐year requirement was insufficient, but expressed difficulty engaging LKDs for even this short time and inadequate resources for longer‐term follow‐up. Participants believed an mHealth system for post‐donation follow‐up could benefit LKDs (by simplifying communication/tasks and improving donor engagement) and transplant centers (by streamlining communication and decreasing workforce burden). Concerns included cost, learning curves, security/privacy, patient language/socioeconomic barriers, and older donor comfort with mHealth technology.Conclusions: Transplant providers felt that mHealth technology could improve LKD follow‐up and help centers meet reporting thresholds. However, designing a secure, easy to use, and cost‐effective system remains challenging.


  • Open Access

    The Impact of the mKidney mHealth System on Live Donor Follow-Up Compliance: Protocol for a Randomized Controlled Trial

    by Macey L Henderson, Alvin G Thomas, Ann K Eno, Madeleine M Waldram, Jaclyn Bannon, Allan B Massie, Michael A Levan, Dorry L Segev, Adam W Bingaman

    Background: Every year, more than 5500 healthy people in the United States donate a kidney for the medical benefit of another person. The Organ Procurement and Transplantation Network (OPTN) requires transplant hospitals to monitor living kidney donors (LKDs) for 2 years postdonation. However, the majority (115/202, 57%) of transplant hospitals in the United States continue to fail to meet nationally mandated requirements for LKD follow-up. A novel method for collecting LKD follow-up is needed to ease both the transplant hospital-level and patient-level burden. We built mKidney—a mobile health (mHealth) system designed specifically to facilitate the collection and reporting of OPTN-required LKD follow-up data. The mKidney mobile app was developed on the basis of input elicited from LKDs, transplant providers, and thought leaders. Objective: The primary objective of this study is to evaluate the impact of the mKidney smartphone app on LKD follow-up rates. Methods: We will conduct a two-arm randomized controlled trial (RCT) with LKDs who undergo LKD transplantation at Methodist Specialty and Transplant Hospital in San Antonio, Texas. Eligible participants will be recruited in-person by a study team member at their 1-week postdonation clinical visit and randomly assigned to the intervention or control arm (1:1). Participants in the intervention arm will receive the mHealth intervention (mKidney), and participants in the control arm will receive the current standard of follow-up care. Our primary outcome will be policy-defined complete (all components addressed) and timely (60 days before or after the expected visit date) submission of LKD follow-up data at required 6-month, 1-year, and 2-year visits. Our secondary outcome will be hospital-level compliance with OPTN reporting requirements at each visit. Data analysis will follow the intention-to-treat principle. Additionally, we will collect quantitative and qualitative process data regarding the implementation of the mKidney system. Results: We began recruitment for this RCT in May 2018. We plan to enroll 400 LKDs over 2 years and follow participants for the 2-year mandated follow-up period. Conclusions: This pilot RCT will evaluate the impact of the mKidney system on rates of LKD and hospital compliance with OPTN-mandated LKD follow-up at a large LKD transplant hospital. It will provide valuable information on strategies for implementing such a system in a clinical setting and inform effect sizes for future RCT sample size calculations. International Registered Report Identifier (IRRID): DERR1-10.2196/11000


  • Open Access

    Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change

    by Tanveen Ishaque, Allan B. Massie, Mary G. Bowring, Christine E. Haugen, Jessica M. Ruck, Samantha E. Halpern, Madeleine M. Waldram, Macey L. Henderson, Jacqueline M. Garonzik Wang, Andrew M. Cameron, et al.